GNOM - M&A Activity A Favored Prescription For Biopharmaceutical Companies
By Andy Acker, CFA
Global Life Sciences Portfolio Manager Andy Acker discusses how large-cap biopharmaceutical companies utilize M&A strategies to fill product pipelines and maintain steady cash flows.
Transcript
Andy Acker: Earlier this week, AbbVie ([[ABBV]]) announced the acquisition of Allergan ([[AGN]]) for $63 billion. This is actually... it is interesting, because this is the third major acquisition we have seen in the biopharmaceutical sector in just the last 18 months, and this is the third deal of over $60 billion. In this case, AbbVie is paying $63 billion, which represented a 45% premium.